Beam Therapeutics Inc. (BEAM)
NASDAQ: BEAM · Real-Time Price · USD
17.24
+0.02 (0.12%)
At close: May 22, 2025, 4:00 PM
17.44
+0.20 (1.16%)
After-hours: May 22, 2025, 7:56 PM EDT
Beam Therapeutics Employees
Beam Therapeutics had 483 employees as of December 31, 2024. The number of employees increased by 47 or 10.78% compared to the previous year.
Employees
483
Change (1Y)
47
Growth (1Y)
10.78%
Revenue / Employee
$131,631
Profits / Employee
-$801,952
Market Cap
1.68B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
BEAM News
- 8 days ago - Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress - GlobeNewsWire
- 9 days ago - Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference - GlobeNewsWire
- 10 days ago - Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) - GlobeNewsWire
- 16 days ago - Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 6 weeks ago - Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress - GlobeNewsWire
- 7 weeks ago - Biotech stocks plunge as FDA's Peter Marks resigns over RFK Jr. dispute, Moderna and Beam Therapeutics hit hard - Invezz
- 2 months ago - Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration - GlobeNewsWire
- 2 months ago - Upgrading Beam Therapeutics: Promising BEAM-302 Data Opens Door For Durable Gene Therapy - Seeking Alpha